Ginkgo and Boehringer Ingelheim join forces for microbial molecule discovery.

Ginkgo Bioworks has partnered with Boehringer Ingelheim in a deal worth up to $406m, using its microbe-based database to find new molecules that the German pharma company could turn into new drugs. The deal includes upfront research and development fees, as well as payments based on hitting R&D, regulatory and commercial markers, and royalties on sales.